Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3635) 3635
Publication (298) 298
Newsletter (239) 239
Book Review (78) 78
Conference Proceeding (64) 64
Newspaper Article (41) 41
Book Chapter (12) 12
Magazine Article (7) 7
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abatacept (3584) 3584
humans (2097) 2097
animals (1485) 1485
ctla-4 antigen (1398) 1398
immunoconjugates (1375) 1375
index medicus (1148) 1148
antigens, cd (1139) 1139
immunology (1077) 1077
mice (995) 995
female (991) 991
male (924) 924
rheumatoid arthritis (815) 815
rheumatology (712) 712
t-lymphocytes - immunology (586) 586
immunoconjugates - therapeutic use (584) 584
arthritis, rheumatoid - drug therapy (563) 563
antirheumatic agents - therapeutic use (527) 527
transplantation (526) 526
middle aged (520) 520
adult (474) 474
immunosuppressive agents - therapeutic use (436) 436
treatment outcome (425) 425
ctla-4 (421) 421
antigens, differentiation - genetics (410) 410
lymphocyte activation (404) 404
rheumatoid factor (403) 403
antigens, differentiation - immunology (395) 395
arthritis (393) 393
t cells (372) 372
surgery (358) 358
expression (355) 355
cd28 (354) 354
mice, inbred c57bl (352) 352
double-blind (346) 346
rituximab (342) 342
activation (332) 332
mice, inbred balb c (318) 318
research (302) 302
aged (301) 301
care and treatment (288) 288
methotrexate (287) 287
costimulation (283) 283
immunosuppressive agents - pharmacology (272) 272
cd28 antigens - immunology (268) 268
rats (267) 267
antigens, differentiation - metabolism (264) 264
in-vivo (264) 264
abatacept - therapeutic use (256) 256
antibodies, monoclonal - therapeutic use (251) 251
analysis (243) 243
b7-2 antigen (235) 235
induction (230) 230
rheumatoid-arthritis (230) 230
medicine, research & experimental (227) 227
drug therapy (222) 222
tumor necrosis factor-alpha - antagonists & inhibitors (221) 221
antigens, differentiation - physiology (220) 220
cells, cultured (217) 217
b7-1 antigen - immunology (212) 212
graft rejection - prevention & control (212) 212
lymphocytes (212) 212
disease (211) 211
time factors (210) 210
infliximab (206) 206
antirheumatic agents - adverse effects (205) 205
therapy (204) 204
cd4-positive t-lymphocytes - immunology (203) 203
immunoconjugates - pharmacology (203) 203
tolerance (198) 198
immunosuppression (193) 193
efficacy (190) 190
immunoconjugates - adverse effects (189) 189
safety (189) 189
tocilizumab (189) 189
adalimumab (184) 184
receptor (183) 183
etanercept (182) 182
transplantation, homologous (179) 179
antigen (174) 174
molecular sequence data (174) 174
graft rejection - immunology (172) 172
arthritis, rheumatoid - immunology (171) 171
pharmacology & pharmacy (171) 171
cd28 antigens - metabolism (169) 169
dendritic cells (169) 169
antigens, differentiation - pharmacology (168) 168
immunotherapy (167) 167
monoclonal-antibody (165) 165
drug therapy, combination (164) 164
t-cell activation (164) 164
t-cells (161) 161
b7-1 antigen - metabolism (156) 156
health aspects (154) 154
kidney transplantation (154) 154
lymphocyte activation - immunology (154) 154
rats, inbred lew (153) 153
antirheumatic agents (151) 151
inadequate response (150) 150
t-lymphocytes - drug effects (149) 149
risk factors (148) 148
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3706) 3706
Japanese (54) 54
German (48) 48
French (45) 45
Spanish (29) 29
Chinese (26) 26
Russian (9) 9
Czech (6) 6
Hungarian (6) 6
Portuguese (6) 6
Italian (5) 5
Polish (5) 5
Danish (3) 3
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Abatacept dans le traitement du rhumatisme psoriasique actif: resultats a 24 semaines d'une etude de phase III
by Mease, P.J and Gottlieb, A.B and Van Der Heijde, D and Fitzgerald, O and Johnsen, A and Nys, M and Banerjee, S and Gladman, D
Revue du rhumatisme, ISSN 1169-8330, 11/2016, Volume 83, p. A98-A99
Abatacept
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Abatacept: A Review in Rheumatoid Arthritis
by Blair, Hannah A and Deeks, Emma D
Drugs, ISSN 0012-6667, 7/2017, Volume 77, Issue 11, pp. 1221 - 1233
The biological DMARD (bDMARD) abatacept (Orencia®), a recombinant fusion protein, selectively modulates a co-stimulatory signal necessary for T-cell... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | SUBCUTANEOUS ABATACEPT | RADIOGRAPHIC PROGRESSION | CO-STIMULATION MODULATOR | INADEQUATE RESPONSE | LONG-TERM SAFETY | PHASE IIIB | PHARMACOLOGY & PHARMACY | INTRAVENOUS ABATACEPT | TOXICOLOGY | METHOTREXATE-NAIVE PATIENTS | HEAD-TO-HEAD | DAMAGE PROGRESSION | Abatacept - pharmacology | Antirheumatic Agents - administration & dosage | Humans | Treatment Outcome | Clinical Trials as Topic | Methotrexate - therapeutic use | Methotrexate - adverse effects | Abatacept - adverse effects | Immunoconjugates - pharmacology | Arthritis, Rheumatoid - drug therapy | Abatacept - therapeutic use | Immunoconjugates - therapeutic use | Adult | Antirheumatic Agents - pharmacokinetics | Methotrexate - administration & dosage | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Care and treatment | Usage | Dosage and administration | Abatacept | Drug therapy | Rheumatoid arthritis | Intravenous administration | Pathogenesis | Clinical trials | Systematic review | Lymphocytes T | Arthritis | Proteins | Cell activation | Lymphocytes | Remission | Methotrexate | Fusion protein | Recombinant | Antigens | Signs and symptoms | Biological products | Rheumatology | T cell receptors | Patients | Immunogenicity | Tumor necrosis factor | Structural damage | TNF inhibitors | Cost analysis | Health risk assessment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Maintenance therapy for rheumatoid arthritis
by Panesar, Kiran
U.S. Pharmacist, ISSN 0148-4818, 10/2011, Volume 36, Issue 10, pp. 60 - 68
Journal Article
Details down arrow
4. Full Text Manque d'efficacite de l'abatacept dans le traitement des spondylarthropathies axiales refractaires aux anti-TNF-[alpha]
Revue du rhumatisme, ISSN 1169-8330, 01/2013, Volume 80, Issue 1, p. 46
Evaluer l'efficacite de l'abatacept chez les patients ayant une spondylarthropathie (SpA) axiale refractaire au traitement par anti-TNF-[alpha]. 
Abatacept
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Neue Anti-B-Zell-Strategien fur die Therapie rheumatischer Erkrankungen
by Tarner, I.H
Zeitschrift fur Rheumatologie, ISSN 0340-1855, 07/2009, Volume 68, Issue 5, p. 380
Der klinische Erfolg der Depletierung von B-Zellen durch den Anti-CD20-Antikorper Rituximab hat eine neue Ara in der Therapie rheumatischer Erkrankungen... 
Abatacept
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Abatacept for the treatment of systemic lupus erythematosus
by Pimentel-Quiroz, Victor R and Ugarte-Gil, Manuel F and Alarcón, Graciela S
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 04/2016, Volume 25, Issue 4, pp. 493 - 499
Introduction: Due to improvements in our understanding of the pathogenesis of systemic lupus erythematosus (SLE), several target drugs have been and are being... 
treatment | lupus nephritis | Systemic lupus erythematosus | abatacept | MANAGEMENT | EFFICACY | CYCLOPHOSPHAMIDE | SAFETY | METHYLPREDNISOLONE | TRIAL | DISEASE | MURINE LUPUS | DOUBLE-BLIND | NEPHRITIS | PHARMACOLOGY & PHARMACY | Abatacept - pharmacology | Abatacept - adverse effects | Immunologic Factors - chemistry | Animals | Abatacept - therapeutic use | Humans | Lupus Erythematosus, Systemic - drug therapy | Abatacept - chemistry | Lupus Erythematosus, Systemic - metabolism | Immunologic Factors - adverse effects | Immunologic Factors - pharmacology | Immunologic Factors - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Abatacept without Methotrexate in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of a Phase III, Randomized Study
by Strand, V and Lehman, T and Ahmad, HA and Johnsen, A and Balachandar, S and Mease, PJ
ARTHRITIS & RHEUMATOLOGY, ISSN 2326-5191, 09/2018, Volume 70
RHEUMATOLOGY
Conference Proceeding
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Safety profile of biological therapies for treating rheumatoid arthritis
by Cañete, Juan D and Hernández, Ma Victoria and Sanmartí, Raimon
Expert Opinion on Biological Therapy, ISSN 1471-2598, 09/2017, Volume 17, Issue 9, pp. 1089 - 1103
Introduction: Biological agents such as tumor necrosis factor inhibitors (TNFi), abatacept, rituximab and tocilizumab have proven efficacy in RA. However,... 
TNF antagonists | tocilizumab | abatacept | Biological therapy | drug risk | adverse events | rituximab | MEDICINE, RESEARCH & EXPERIMENTAL | MODIFYING ANTIRHEUMATIC DRUGS | RISK-FACTORS | HEART-FAILURE | ANTI-TNF THERAPY | FACTOR-ALPHA | SUBCUTANEOUS ABATACEPT | TUMOR-NECROSIS-FACTOR | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | FACTOR INHIBITORS | BRITISH-SOCIETY | SERIOUS INFECTIONS | Tumor Necrosis Factor-alpha - metabolism | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Bacterial Infections - etiology | Humans | Risk Factors | Virus Diseases - etiology | Rituximab - therapeutic use | Abatacept - adverse effects | Arthritis, Rheumatoid - drug therapy | Abatacept - therapeutic use | Antirheumatic Agents - adverse effects | Abatacept - immunology | Rituximab - immunology | Antibodies, Monoclonal, Humanized - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Rituximab - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
by Alten, Rieke and Bingham, Clifton O and Cohen, Stanley B and Curtis, Jeffrey R and Kelly, Sheila and Wong, Dennis and Genovese, Mark C
BMC Musculoskeletal Disorders, ISSN 1471-2474, 05/2016, Volume 17, Issue 1, p. 231
Background: Patients with rheumatoid arthritis (RA), including those treated with biologics, are at increased risk of some vaccine-preventable infections. We... 
Pneumococcal | Immunization | Abatacept | Influenza | Rheumatoid arthritis | Vaccination | MODIFYING ANTIRHEUMATIC DRUGS | CONJUGATE VACCINE | SAFETY | METHOTREXATE | RHEUMATOLOGY | SUBCUTANEOUS ABATACEPT | IMMUNOGENICITY | THERAPY | RECOMMENDATIONS | COSTIMULATION | POLYSACCHARIDE VACCINE | ORTHOPEDICS | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antirheumatic Agents - immunology | Male | Antibodies, Viral - blood | Abatacept - administration & dosage | Arthritis, Rheumatoid - drug therapy | Injections, Subcutaneous | Abatacept - immunology | Adult | Female | Pneumococcal Vaccines - adverse effects | Antibodies, Bacterial - blood | Immunosuppressive Agents - administration & dosage | Antirheumatic Agents - therapeutic use | Influenza Vaccines - adverse effects | Influenza Vaccines - immunology | Immunosuppressive Agents - immunology | Abatacept - therapeutic use | Pneumococcal Infections - prevention & control | Pneumococcal Vaccines - immunology | Arthritis, Rheumatoid - immunology | Influenza, Human - prevention & control | Influenza vaccines | Analysis | Dosage and administration | Drug therapy | Pneumococcal vaccine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
by Mease, Philip J and Gottlieb, Alice B and van der Heijde, Désirée and FitzGerald, Oliver and Johnsen, Alyssa and Nys, Marleen and Banerjee, Subhashis and Gladman, Dafna D
Annals of the Rheumatic Diseases, ISSN 0003-4967, 09/2017, Volume 76, Issue 9, pp. 1550 - 1558
ObjectivesTo assess the efficacy and safety of abatacept, a selective T-cell costimulation modulator, in a phase III study in psoriatic arthritis... 
DMARDs (biologic) | Treatment | T cells | Psoriatic arthritis | RHEUMATOID-ARTHRITIS | SUBCUTANEOUS ABATACEPT | TRIAL | MULTICENTER | THERAPY | INADEQUATE RESPONSE | METHOTREXATE | MONOCLONAL-ANTIBODY | FUTURE 2 | RHEUMATOLOGY | DISEASE-ACTIVITY | Pneumonia, Pneumocystis - etiology | Double-Blind Method | Arthritis, Psoriatic - physiopathology | Humans | Middle Aged | Pneumonia, Pneumocystis - immunology | Male | Treatment Outcome | Abatacept - therapeutic use | Arthritis, Psoriatic - drug therapy | Quality of Life | Adult | Female | Immunocompromised Host | Antirheumatic Agents - therapeutic use | Care and treatment | Dosage and administration | Safety and security measures | Abatacept | Antigens | Statistical analysis | Psoriasis | Cytokines | Dermatology | Rheumatology | Lymphocytes T | Arthritis | Patients | Necrosis | Lymphocytes | Tumor necrosis factor | Rheumatoid arthritis | TNF inhibitors | Tumor necrosis factor-TNF | Clinical medicine | Drug dosages | Tumors | Clinical and Epidemiological Research | 2311 | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text MENTAL HEALTH BENEFITS ASSOCIATED WITH REDUCTION IN DISEASE ACTIVITY AMONG RHEUMATOID ARTHRITIS PATIENTS: A SYSTEMATIC REVIEW OF THE LITERATURE
by Strand, V and Rendas-Baum, R and Kosinski, M and Brooks, D and Ganguly, R
ANNALS OF THE RHEUMATIC DISEASES, ISSN 0003-4967, 06/2017, Volume 76, pp. 816 - 816
RHEUMATOLOGY | ABATACEPT
Conference Proceeding
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis
by Nakachi, Shinichiro and Sumitomo, Shuji and Tsuchida, Yumi and Tsuchiya, Haruka and Kono, Masanori and Kato, Rika and Sakurai, Keiichi and Hanata, Norio and Nagafuchi, Yasuo and Tateishi, Shoko and Kanda, Hiroko and Okamura, Tomohisa and Yamamoto, Kazuhiko and Fujio, Keishi
Arthritis Research and Therapy, ISSN 1478-6354, 05/2017, Volume 19, Issue 1, pp. 97 - 11
Background: Regulatory T cells (Tregs) play a role in the suppression of inflammation in autoimmune diseases, and lymphocyte activation gene 3 (LAG3) was... 
LAG3 | Abatacept | Antibody production | Rheumatoid arthritis | IL-10 | Regulatory T cell | SYSTEMIC-LUPUS-ERYTHEMATOSUS | CTLA4-IG ABATACEPT | RECEPTOR | RHEUMATOLOGY | TYPE-1 CELLS | CUTTING EDGE | B-CELLS | PATHOGENESIS | THERAPY | SELF-TOLERANCE | TH17 CELLS | Abatacept - pharmacology | Leukocytes, Mononuclear - metabolism | T-Lymphocytes, Regulatory - metabolism | Leukocytes, Mononuclear - drug effects | Antigens, CD - biosynthesis | Coculture Techniques | Humans | Middle Aged | Male | Treatment Outcome | Disease Progression | T-Lymphocytes, Regulatory - immunology | Arthritis, Rheumatoid - metabolism | T-Lymphocytes, Regulatory - drug effects | Arthritis, Rheumatoid - drug therapy | Abatacept - therapeutic use | Leukocytes, Mononuclear - immunology | Adult | Female | Interleukin-10 - biosynthesis | Aged | Antirheumatic Agents - pharmacology | Arthritis, Rheumatoid - immunology | Antirheumatic Agents - therapeutic use | Lymphocyte receptors | Antigens | Cytokines | Rheumatology | T cell receptors | Proteins | Immunology | Lymphocytes | Tumor necrosis factor-TNF | Life sciences | Autoimmune diseases | Chemokines
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
by Mercer, Louise K and Askling, Johan and Raaschou, Pauline and Dixon, William G and Dreyer, Lene and Hetland, Merete Lund and Strangfeld, Anja and Zink, Angela and Mariette, Xavier and Finckh, Axel and Canhao, Helena and Iannone, Florenzo and Zavada, Jakub and Morel, Jacques and Gottenberg, Jacques-Eric and Hyrich, Kimme L and Listing, Joachim
Annals of the Rheumatic Diseases, ISSN 0003-4967, 02/2017, Volume 76, Issue 2, pp. 386 - 391
ObjectivesSome studies have reported a possible association between exposure to tumour necrosis factor (TNF) inhibitors and an increased risk of melanoma. The... 
Rheumatoid Arthritis | Anti-TNF | Epidemiology | POPULATION | REGISTRIES | THERAPY | METAANALYSIS | CANCER-RISK | MALIGNANCIES | TNF-ALPHA | RHEUMATOLOGY | Melanoma - epidemiology | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Risk Factors | Europe - epidemiology | Male | Skin Neoplasms - epidemiology | Incidence | Rituximab - therapeutic use | Arthritis, Rheumatoid - drug therapy | Abatacept - therapeutic use | Aged, 80 and over | Adult | Female | Registries | Aged | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Complications and side effects | Usage | Biological products | Tumor necrosis factor inhibitors | Rheumatoid arthritis | Risk factors | Skin cancer | Clinical and Epidemiological Research | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Limited value of the multi-biomarker disease activity assay compared to the Routine Assessment of Patient Index Data 3 (RAPID3) score in the prognosis of important clinical outcomes in rheumatoid arthritis: comment on the article by Fleischmann et al and accompanying editorial by Davis Reply
by Fleischmann, R and Connolly, SE and Maldonado, MA and Schiff, M
ARTHRITIS & RHEUMATOLOGY, ISSN 2326-5191, 04/2017, Volume 69, Issue 4, pp. 867 - 868
SUBCUTANEOUS ABATACEPT | ADALIMUMAB | VALIDATION | RHEUMATOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text T Cell–Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model
by Oh, Annie L and Mahmud, Nadim and Mahmud, Dolores and Nicolini, Benedetta and Senyuk, Vitalyi and Patel, Pritesh R and Bonetti, Elisa and Arpinati, Mario and Ferrara, James L.M and Rondelli, Damiano
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 12/2017, Volume 23, Issue 12, pp. 2048 - 2056
A xenograft model of stem cell rejection was developed by co-transplantating human CD34 and allogeneic CD3 T cells into NOD-scid É£-chain mice. T cells caused... 
Rejection | Stem cell transplantation | Abatacept | CD34 | T cell | PROGENITOR CELLS | POOR GRAFT FUNCTION | COMPLETE REMISSION | CD34+PROGENITOR CELLS | ACUTE MYELOID-LEUKEMIA | PRESENTING FUNCTION | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | POSTTRANSPLANTATION CYCLOPHOSPHAMIDE | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | BLOOD-CELLS | Abatacept - pharmacology | Antigens, CD34 | Reoperation | CD3 Complex | Graft Rejection - prevention & control | Humans | Graft Rejection - etiology | T-Lymphocytes - transplantation | Abatacept - administration & dosage | Animals | Heterografts | Time Factors | Abatacept - therapeutic use | Mice, Inbred NOD | T-Lymphocytes - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text ASP2408 and ASP2409, novel CTLA4-Ig variants with CD86-selective ligand binding activity and improved immunosuppressive potency, created by directed evolution
by Oshima, Shinsuke and Karrer, Erik E and Paidhungat, Madan M and Neighbors, Margaret and Chapin, Steven J and Fan, Rong A and Reed, Margaret A and Wu, Kuoting and Wong, Clifford and Chen, Yonghong and Whitlow, Marc and Anderson, Francisco A and Bam, Rujuta A and Zhang, Qian and Larsen, Brent R and Viswanathan, Sridhar and Devens, Bruce H and Bass, Steven H and Higashi, Yasuyuki
Protein Engineering, Design and Selection, ISSN 1741-0126, 05/2016, Volume 29, Issue 5, pp. 159 - 167
Abstract The CTLA4-Ig therapeutics abatacept and belatacept inhibit CD28-mediated T cell activation by binding CD80 (B7-1) and CD86 (B7-2) co-stimulatory... 
costimulation blockade | phage display | rheumatoid arthritis | next-generation protein therapeutics | transplantation | Abatacept - pharmacology | Amino Acid Sequence | Immunoconjugates - metabolism | Abatacept - metabolism | Humans | Abatacept - chemistry | Cercopithecus aethiops | Models, Molecular | Substrate Specificity | Directed Molecular Evolution | Abatacept - genetics | Immunoconjugates - chemistry | B7-2 Antigen - metabolism | Immunoconjugates - pharmacology | Animals | Immunosuppressive Agents - metabolism | Female | Ligands | Protein Conformation | Mice | COS Cells | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - chemistry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Influence de l'obesite sur l'efficacite de differents agents biologiques dans les maladies inflammatoires : revue systematique et meta-analyse
by Shan, Juan and Zhang, Jiabi
Revue du rhumatisme, ISSN 1169-8330, 07/2019, Volume 86, Issue 4, p. 326
Resume L'obesite est une epidemie mondiale dont un nombre croissant d'elements probants suggere une influence sur la reponse de l'organisme aux traitements... 
Psoriasis | Abatacept | Lymphocytes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Pharmaceutical approval update
by Goldenberg, Marvin M
P and T, ISSN 1052-1372, 03/2006, Volume 31, Issue 3, pp. 149 - 153
Journal Article
Details down arrow
19. Full Text Reactivation of occult hepatitis B virus infection under treatment with abatacept: A case report
by Talotta, Rossella and Atzeni, Fabiola and Sarzi Puttini, Piercarlo
BMC Pharmacology and Toxicology, ISSN 2050-6511, 04/2016, Volume 17, Issue 1, pp. 17 - 17
Background: Abatacept (ABA) is a fusion receptor protein containing the CTLA-4 domain that prevents the activation of naive T cells by binding the CD80 and... 
Reactivation | Abatacept | Rheumatoid arthritis | Hepatitis B | RHEUMATOID-ARTHRITIS | RECOMMENDATIONS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | Hepatitis B Antibodies - analysis | Hepatitis B, Chronic - immunology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Humans | Male | Methotrexate - therapeutic use | Arthritis, Rheumatoid - complications | Abatacept - administration & dosage | Asymptomatic Infections | Drug Therapy, Combination - adverse effects | Arthritis, Rheumatoid - drug therapy | Lamivudine - therapeutic use | Antirheumatic Agents - adverse effects | Hepatitis B virus - immunology | Antirheumatic Agents - therapeutic use | Antiviral Agents - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis B virus - physiology | Arthritis, Rheumatoid - virology | DNA, Viral - blood | Hepatitis B, Chronic - virology | Hepatitis B virus - drug effects | Abatacept - adverse effects | Hepatitis B, Chronic - complications | Hepatitis B, Chronic - drug therapy | Virus Activation - drug effects | Abatacept - therapeutic use | Aged | Hepatitis B virus - isolation & purification | Infusions, Intravenous | Drug Monitoring | Corticosteroids | Dendritic cells | Immunoglobulin G | Liver | Lamivudine | Arthritis | Prednisone | T cells | Infection | Rheumatoid factor | Methotrexate | Drug therapy | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text THERAPEUTIC DRUG MONITORING OF BELATACEPT IN KIDNEY TRANSPLANTATION
by de raav, Gretchen N and Bergan, Stein and Baan, Carla C and Weimar, Willem and van elder, Teun and Hesselink, Dennis A
Therapeutic Drug Monitoring, ISSN 0163-4356, 12/2014, Volume 37, Issue 5, pp. 560 - 567
Belatacept is a novel immunosuppressive drug that inhibits the co-stimulatory signal required for T-cell activation and has been approved for the prevention of... 
Therapeutic drug monitoring | Belatacept | Transplantation | Co-stimulatory signal | Kidney | CELLS | SAFETY | PHASE-III | RECIPIENTS | REGIMENS | COSTIMULATION BLOCKADE | kidney | RESPONSES | transplantation | PHARMACOLOGY & PHARMACY | co-stimulatory signal | TOXICOLOGY | belatacept | MEDICAL LABORATORY TECHNOLOGY | therapeutic drug monitoring | ABATACEPT | EXPOSURE | CYCLOSPORINE | Abatacept - pharmacology | Glomerular Filtration Rate | Enzyme-Linked Immunosorbent Assay | Humans | B7-2 Antigen - analysis | Dose-Response Relationship, Drug | Tissue Distribution | Immunosuppressive Agents - blood | Abatacept - blood | Abatacept - immunology | CTLA-4 Antigen - antagonists & inhibitors | Drug Monitoring | Kidney Transplantation - adverse effects | Immunoassay | Immunology | Transplants & implants | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights